bioRxivMolecular BiologyPreprint
Circulating tumor cell characterization and classification by novel combinatorial dual-color (CoDuCo) in situ hybridization and supervised machine learning
Lilli BonstingliD, Margret Zinnegger, Katja SallingeriD, Karin Pankratz, Elisabeth Pritz, Corinna Odar, Christina Skofler, Christine Ulz, Lisa Oberauner‐Wappis, Anatol Borrás-CherrieriD, Višnja Somođi, Ellen HeitzeriD, Thomas KroneisiD, Thomas BauernhoferiD, Amin El HeliebiiD
Abstract
Metastatic prostate cancer is a highly heterogeneous and dynamic disease and practicable tools for patient stratification and resistance monitoring are urgently needed. Liquid biopsy analysis of circulating tumor DNA and circulating tumor cells (CTCs) are promising, but due to the diversity of resistance mechanisms, comprehensive testing is essential. Previously, we demonstrated that CTCs can be characterized by mRNA-based in situ padlock probe hybridization. Now, we have developed a novel combinatorial dual-color (CoDuCo) approach with increased multiplex capacity of up to 15 distinct markers, complemented by semi-automated image analysis and machine learning-assisted CTC classification. Here, we present three exemplary cases of patient samples in which the CoDuCo assay visualized diverse resistance mechanisms (AR-V7, neuroendocrine differentiation (SYP, CHGA, NCAM1)), as well as druggable targets and predictive markers (PSMA, DLL3, SLFN11). The combination of high multiplex capacity and microscopy-based single-cell analysis is a unique and powerful feature of the CoDuCo in situ assay. This synergy enables the identification and characterization of CTCs with epithelial, epithelial-mesenchymal, and neuroendocrine phenotypes, the detection of CTC clusters, and the visualization of CTC heterogeneity. In conclusion, the assay is a promising tool for monitoring the dynamic molecular changes associated with drug response and resistance in prostate cancer. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=134 SRC="FIGDIR/small/592946v1_ufig1.gif" ALT="Figure 1"> View larger version (50K): org.highwire.dtl.DTLVardef@46a186org.highwire.dtl.DTLVardef@116824dorg.highwire.dtl.DTLVardef@c4c842org.highwire.dtl.DTLVardef@1378b67_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: CITE-seq
- assay: spatial transcriptomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell-cell communication
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: statistical model
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Deep multiplexed 50-marker imaging of circulating tumor cells expands actionable biomarker profiling for precision oncology
Timothy J. Mann, Ye Zheng, … John George Lock·bioRxiv·Oct 23, 2025
- Low abundance of circulating tumor DNA in localized prostate cancer
S. Thomas Hennigan, Shana Y. Trostel, … Adam G. Sowalsky·JCO Precision OncologyPeer-reviewed·Sep 9, 2019
- Strategies of mechanical adaptations of circulating tumor cells and properties of their cellular microenvironment have predictive and prognostic biomarker value
Maria Gaczynska, Fatemeh Ataei, … Pawel A Osmulski·bioRxiv·Nov 2, 2026
- Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
Markus Mayrhofer, Bram De Laere, … Johan Lindberg·Genome MedicinePeer-reviewed·Nov 19, 2018
- Dynamics of circulating tumor cell subsets defined by PSMA and EpCAM predict survival in metastatic castration-resistant prostate cancer patients treated with 177Lu-PSMA-617
Madeline J. Lee, Lauren Yu, … Ali T. Arafa·bioRxiv·Sep 16, 2026
- Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies
S. Zaidi, J. Park, … C. Sawyers·bioRxiv·Apr 9, 2024